Journals / Türk Toraks Dergisi / 2010 / Cilt: 11 - Sayı: 4

Immunohistochemistry for differentiation of pleural epithelioid malignant mesothelioma from adenocarcinoma: A panel for selection

Plevral epiteloid malign mezotelyoma ile adenokarsinom ayırıcı tanısında immünhistokimya; bir panel önerisi

Pages
144–148
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We consider that, if there is any inconsistency between the results of staining with these six markers, other antibodies should be incorporated into the panel.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: An important difficulty pathologists confront concerning thoracic pathology is the differentiation of pleural epithelioid malignant mesothelioma from pulmonary adenocarcinoma infiltrating into the pleura or metastatic adenocarcinoma.
📊
Key Findings & Data:Results: Most frequently used markers were calretinin and CK5/6 for epithelioid malignant mesothelioma and CEA, CD15 and TTF-1 for adenocarcinoma.
💡
Conclusion & Impact:We consider that, if there is any inconsistency between the results of staining with these six markers, other antibodies should be incorporated into the panel.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: An important difficulty pathologists confront concerning thoracic pathology is the differentiation of pleural epithelioid malignant mesothelioma from pulmonary adenocarcinoma infiltrating into the pleura or metastatic adenocarcinoma. Since epithelioid malignant mesothelioma may depict microscopic patterns similar to adenocarcinoma, morphological findings may not be sufficient to make a differential diagnosis. Up to now, many immunohistochemical markers have been proposed for their differentiation and there have been many studies on the sensitivity and specifity of each marker. Material and Method: In this study we retrospectively evaluated the reports on patients diagnosed as pleural epithelial MM and patients diagnosed as adenocarcinoma infiltrating into the pleura for the past seven years and determined the immunohistochemical markers used for differential diagnosis. Results: Most frequently used markers were calretinin and CK5/6 for epithelioid malignant mesothelioma and CEA, CD15 and TTF-1 for adenocarcinoma. EMA was used in both groups. Conclusion: We found that a panel including calretinin and CK5/6 for malignant mesothelioma and CEA and CD15 for adenocarcinoma and additionally EMA and TTF-1 avoided the difficulty in all cases. We consider that, if there is any inconsistency between the results of staining with these six markers, other antibodies should be incorporated into the panel.

Özet

Amaç: Toraks patolojisi pratiğinde karşımıza çıkan önemli sorunlardan biri plevral epiteloid malign mezotelyoma ile plevrayı infiltre eden pulmoner adenokarsinomun ya da metastatik adenokarsinomun ayırıcı tanısının yapılmasıdır. Epiteloid malign mezotelyoma, adenokarsinoma benzer mikroskopik paternler gösterebildiğinden ayırıcı tanıda morfolojik bulgular yetersiz kalmaktadır. Bu ayırımın yapılabilmesi için günümüze değin pek çok immünhistokimyasal işaretleyici öne sürülmüş ve her biri için sensitivite ve spesifiteyi araştıran çok sayıda makale yayınlanmıştır. Gereç ve Yöntem: Bu çalışmada bölümümüzde son 7 yıl içinde tanı almış plevral epitelyal malign mezotelyoma olguları ile plevrayı infiltre etmiş adenokarsinom olgularına ait raporlar incelenmiş, bu olgularda ayırıcı tanıya giderken kullanılan immünhistokimyasal işaretleyiciler değerlendirilmiştir. Bulgular: En sık kullanılan işaretleyiciler epiteloid malign mezotelyoma için kalretinin ve CK5/6, adenokarsinom için CEA, CD15 ve TTF-1 idi. Her iki grupda da EMA çalışılmıştı. Sonuç: Laboratuarımızda epiteloid malign mezotelyoma açısından kalretinin, CK5/6, adenokarsinom açısından CEA ve CD15 ve bunlara eklenen EMA ve TTF-1’den oluşan bir panelin hemen tüm olgularda sorunu çözdüğünü gördük. Uygulanan bu panelin sonuçlarında bir uyumsuzluk izlendiği takdirde diğer antikorların eklenmesinin uygun olacağını düşünmekteyiz

🔖

Cite This Article

AKYILDIZ, E. Ü., ÖZ, B., AKI, H., DEMİRKAYA, A. (2010). Immunohistochemistry for differentiation of pleural epithelioid malignant mesothelioma from adenocarcinoma: A panel for selection. Türk Toraks Dergisi, Cilt: 11 - Sayı: 4, 144–148. https://ajindex.com/articles/329657

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ordóñez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol 1999;112:75-89
  2. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-51
  3. Ordóñez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005;129:1407-14
  4. Comin CE, Novelli L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001;32:529-36
  5. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002;55:662-8
  6. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006;19:514-23
  7. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006;49:561-8
  8. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 2008;132:397-401
  9. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-7
  10. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-46
  11. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 2006;19:417-28
  12. Benjamin CJ, Ritchie AC. Histological staining for the diagnosis of mesothelioma. Am J Med Technol 1982;48:905-8
  13. Seyhan EC, Çetinkaya E, Altın S, ve ark. Akciğer adenokarsinomu ve malign mezotelyoma ayırıcı tanısında immünhistokimyasal analiz. Toraks Dergisi 2007;8:202-6
  14. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologi